PR-15
Source PR-15 at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
PR-15 is an experimental platelet glycoprotein VI (GPVI) adhesion antagonist being investigated as a novel antiplatelet agent. It is mentioned in a review of emerging antiplatelet drugs alongside agents such as prasugrel and ticagrelor. No clinical trial data are provided, and its regulatory status, approved indications, or commercial availability are not established.
Mechanism of Action
PR-15 is designed to block the interaction between platelet GPVI and collagen or other vascular subendothelial components. By antagonizing GPVI‑mediated adhesion, the compound aims to reduce platelet activation and aggregation that contribute to atherothrombotic events. This mechanism differs from the ADP‑P2Y12 inhibition of clopidogrel or the cyclo‑oxygenase inhibition of aspirin.
What the Research Shows
The only source mentioning PR-15 is a 2009 review of novel antiplatelet agents. The authors list PR-15 as a platelet GPVI adhesion antagonist under development by ProCorde GmbH, but the review provides no pre‑clinical or clinical efficacy data, safety findings, pharmacokinetic information, or trial outcomes. Consequently, the scientific literature on PR-15 is limited to its identification as a candidate molecule in the pipeline of next‑generation antiplatelet therapeutics, with no published experimental results to evaluate its performance.
Reported Benefits
If successful, PR-15 could offer a new mechanism to inhibit platelet adhesion, potentially addressing aspirin or clopidogrel resistance and providing additive antithrombotic protection. The GPVI‑targeted approach might reduce platelet‑driven thrombosis while preserving other platelet functions, but these advantages remain theoretical pending empirical testing.
Limitations of the Evidence
No pre‑clinical or clinical data are available, so efficacy, optimal dosing, pharmacokinetics, and comparative advantage over existing agents are unknown. The compound's development stage, regulatory status, and commercial availability are not disclosed, limiting any assessment of its practical utility. Evidence is restricted to a single review citation.
Safety Considerations
Safety information for PR-15 has not been published. Potential adverse effects, contraindications, or drug‑interaction profiles are therefore undetermined. Until formal toxicology or clinical studies are reported, the safety profile remains speculative.
How It Is Administered
The review does not specify the intended route of administration, formulation, or dosing schedule for PR-15. As an experimental antiplatelet agent, its delivery method (e.g., oral, intravenous) has not been documented in the literature.
Routes of Administration
No administration routes recorded yet.
Goals & Uses
No goal associations recorded yet.
Contraindications
No contraindications recorded yet.
Adverse Effects
No adverse effects recorded yet.
Drug Interactions
No drug interactions recorded yet.
Population Constraints
No population constraints recorded yet.
Regulatory Status
No regulatory status recorded yet.
Evidence & Sources
- Journal ArticleModerateInoue K, et al.2014-01-01T00:00:00.000000Z
- Journal ArticleHighSuzuki R, et al.2008-01-01T00:00:00.000000Z
- Journal ArticleModerateAguirre AS, et al.2023-01-01T00:00:00.000000Z
- Journal ArticleModerateShalito I, Kopyleva O, Serebruany V2009-01-01T00:00:00.000000Z
- Journal ArticleModerateNaidoo S, et al.2014-01-01T00:00:00.000000Z
- Journal ArticleModerateSubbiah V, et al.2024-01-01T00:00:00.000000Z
Frequently Asked Questions
What type of drug is PR-15?
PR-15 is described as a platelet glycoprotein VI adhesion antagonist, an experimental molecule being explored for antiplatelet therapy.
How is PR-15 supposed to work?
It is intended to block GPVI‑mediated platelet adhesion to collagen, thereby reducing platelet activation and clot formation.
Has PR-15 been tested in humans?
No human or animal study results have been published; the only mention is in a review that lists it among agents under development.
Are there any known side effects?
Safety data have not been reported, so potential adverse effects, contraindications, or drug interactions are currently unknown.
Is PR-15 available as a prescription drug?
No regulatory approval or commercial availability has been documented; it remains an investigational compound.
What is PR-15?
PR-15 is an experimental platelet glycoprotein VI (GPVI) adhesion antagonist being investigated as a novel antiplatelet agent. It is mentioned in a review of emerging antiplatelet drugs alongside agents such as prasugrel and ticagrelor. No clinical trial data are provided, and its regulatory status, approved indications, or commercial availability are not established.